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ABSTRACT 
TITLE  
             A study of autonomic modulations with short term heart rate variability 
in bronchial asthma patients and its correlation with pulmonary function tests 
BACKGROUND  
             Asthma is a chronic inflammatory disease characterized by airway 
hyper-responsiveness, chronic wheezing, cough and chest tightness. Bronchial 
asthma is associated with positive family history hence the genetic history is 
predisposing factor in development of asthma. The previous studies showed that 
there was an imbalance favoring the parasympathetic system in the asthmatic 
airways. This study was done to compare the autonomic modulation between 
asthmatic patients and normal subjects based on short term heart rate variability. 
METHODS  
             This cross sectional study involved 30 asthmatic patients and 30 normal 
subjects in an age group of 20 to 45 years. Spiropalm digital airflow spirometry 
was used to assess the pulmonary functions. Neviqure digital 
electrocardiography recorder was used to study 5 minutes HRV and Finland 
software was used for analysis of HRV. Data was analyzed by SPSS software 
using independent student t test, Chi square test and Pearson correlation 
analysis. 
RESULTS 
            The time domains measures SDNN, RMSSD, NN50, and pNN50% are 
significantly decreased in asthmatics compared to the normal subjects. The 
frequency domain measures VLF and LF are decreased while HF is increased 
significantly in asthmatic patients. The Chi square test between bronchial 
asthma and positive family history shows that the person with positive family 
history of bronchial asthma has 45 times more chance of getting the disease. 
The Pearson correlation analysis shows HF has significant negative correlation 
with FEV1%. 
CONCLUSION 
            There is a significant increase in central vagal outflow and concomitant 
low sympathetic outflow in asthmatic patients. There is in an increased 
parasympathetic activity with increase in the severity of bronchial asthma. Low 
beat to beat variability is observed in asthmatics which is a predictor of cardiac 
mortality and morbidity. 90% of bronchial patients have positive family history. 
KEYWORDS 
            Heart Rate Variability, Bronchial Asthma, Pulmonary Function Tests. 
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INTRODUCTION 
 
HISTORY OF ASTHMA:  
                              Asthma is derived from the Greek word aazein means 
"panting” and it was first described by Homer. Hippocrates medically defined 
asthma as “anything that causes shortness of breath”1.  
 
                             In 1678, Thomas Willis described asthma as “obstruction of 
bronchi by thick humors, swelling of their walls and obstruction from 
without"2. Roman doctors described asthma as “gasping and the inability to 
breathe without any noise”1. 
 
                            John Floyer in 1698 defined asthma as “laborious respiration 
with lifting of the shoulders and wheezing with intermittent episodes” and that 
the treatment needs rescue and controller therapy1.    
                
                         According to WHO estimate, 235 million people currently 
suffer from asthma. Asthma is the most common chronic disease among 
children. Asthma is a public health problem in all countries.  
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                            Most asthma-related deaths occur in low and lower-middle 
income countries. Asthma is under-diagnosed and under-treated 3. 
 
ASTHMA- AN ALLERGY: 
                             Asthma is a common chronic inflammatory disease of the 
airways characterized by airway hyper-responsiveness, which results in 
reversible increases in bronchial smooth muscle tone, variable amounts of 
inflammation of the bronchial mucosa, recurring symptoms, reversible airflow 
obstruction and bronchospasm3. Asthma is also characterized by episodic or 
chronic wheezing, cough and chest tightness. 
 
                           Global Initiative for Asthma defines asthma as "a chronic 
inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway 
hyper-responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing particularly at night or in the early 
morning. These episodes are usually associated with widespread but variable 
airflow obstruction within the lung that is often reversible either spontaneously 
or with treatment"4. 
 3 
 
SYMPTOMS 
                   Common symptoms and signs of asthma include, 
 Wheezing  
 Coughing 
 Breathing difficulty 
 Tightness in the chest  
 Worsening of symptoms at night 
 Worsening of symptoms on exposure to cold air 
 Appearance of symptoms while exercising 
 Symptoms after exposure to allergens 
 Increased heart rate >80 beats/min and 
 FEV1% and PEFR less than 80%. 
 
                                Running nose, sinus infections, acid reflux disease, 
psychological stress and sleep apnea are the problems that can disturb with 
asthma management4. 
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PATHOPHYSIOLOGY: 
                            In a person with asthma, mucous exudates, goblet cell 
metaplasia, and epithelial basement membrane thickening obstruct the lumen 
of the bronchiole. In asthma the chronic inflammation of the airways results in 
increased contractility of the surrounding smooth muscles. The narrowing of 
the lumen is reversible with or without treatment in asthmatics5.  
 
                           The changes in the airways of the asthmatics also include an 
increase in eosinophils and thickening of the lamina reticularis. Chronically 
the airways smooth muscle may increase in size along with an increase in the 
number of mucous glands5. The association between allergy and asthma has 
been often recognized and plasma IgE levels are often elevated in asthma. 
 
                           The eosinophils release proteins in the inflammatory 
reactions. These proteins may damage the respiratory airway epithelium and 
contribute to hyper-responsiveness. Leukotrines released from eosinophils and 
mast cells can enhance bronchoconstriction. Amines, neuropeptides, 
chemokines and interleukins have effects on contractility of the bronchial 
smooth muscle6. 
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RISK FACTORS FOR ASTHMA:  
             The risk factors for asthma7are 
 environmental factors like allergens 
 tobacco smoking  
 air pollutants 
 occupational sensitizers 
 respiratory infections 
 host factors like airway hyper responsiveness  
 family history of asthma  and  
 atopy.            
 
GENETIC PREDISPOSITION IN ASTHMA: 
                             Asthma can be caused by genetic predisposition. Burke W, 
Fesinmeyer M in his study found, family history as a predictor of asthma risk. 
The prevalence has increased considerably over the past 20 years, recent 
researches have suggested that the risk of allergies in young children is much 
greater when the mother is allergic than the father. The maternal inheritance of 
the allergies may be due to mother's antibodies influence on the child's 
immunity as it is developing in the womb8. 
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                             Fernando Martinez  in his study showed that the complex 
interactions between genetic and environmental factors help in the 
development of asthma. After birth, mother’s milk contains antibodies and 
dietary substances that could alter infant's immunity and alter the risk of 
developing allergies in adult life. He also showed asthma was associated with 
positive family history 9.  
 
                            Mathew A. C emphasized careful evaluation and long term 
follow up should be taken in children with low birth weight and a family 
history of asthma 10.  
 
ASTHMA CLASSIFICATION: 
                           On the basis of onset, asthma is classified into  
• Childhood - onset asthma  
• Adult-onset asthma  
• Exercise-induced asthma 
• Cough-induced asthma 
• Occupational asthma 
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• Nocturnal asthma and  
• Steroid-resistant asthma.  
 
 On the basis of severity of symptoms and signs, asthma is classified as  
• Intermittent asthma 
• Mild asthma 
• Moderate asthma 
• Severe asthma11.  
 
                         Global Initiative for Asthma (GINA) guidelines 2011 classified 
asthma based on FEV1% and respiratory symptoms and exacerbations during 
day and night. Based on GINA guidelines, asthma patients were classified into 
three groups as  
• Controlled  
• Partly controlled and  
• Uncontrolled group4.        
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DIAGNOSING ASTHMA: 
                           Asthma diagnosis are based on three components11, 
• Medical history 
• Physical examination and 
• Results from PFT by spirometer. 
 
SPIROMETER 
                            Spirometer is one of the equipments used for basic 
Pulmonary Function Tests (PFT’s). Spirometry is a physiological and 
noninvasive test. It requires deep breaths and forceful expiration into a tube 
connected to a spirometer. Spirometry measures how an individual inhales or 
exhales volumes of air as a function of time. 
 
                           Volume or flow is the important thing measured using 
spirometry12. The measurements are compared against standards developed for 
a person's age, height and weight measurements. The values below normal 
may indicate obstructed airways.  
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                            The bronchodilator drugs are given to open air passages 
before retesting with the spirometer. If the value improves after giving the 
drug there may the chance for asthma.  
                         
                            The spirogram will identify two different types of abnormal 
ventilation patterns, obstructive and restrictive. Obstructive patterns (eg. 
asthma, bronchitis) are one which affects the rate at which air can be expelled 
from the lungs and is characterized by a reduced forced expiratory volume in 
first second (FEV1), normal forced vital capacity (FVC) and a low FEV1%. 
                                   
                             An FEV1% of <70% is diagnostic of air flow obstruction and 
confirms obstructive disease. Restrictive pattern (eg. kyphosis, scoliosis, 
pulmonary fibrosis) affects lung expansion. FEV1 and FVC are decreased, 
with a normal ratio of   FEV1/FVC13. 
 
                              Reversibility of FEV1 by more than 12% suggests a 
diagnosis of asthma. Spirometer provides an assessment of severity, 
reversibility, variability, confirmation and diagnosis of asthma. The most 
common measurements are FVC, FEV1, FEV1%, and peak expiratory flow rate 
(PEFR).14 
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                                FEV1 is the volume of forced vital capacity expired in 1st 
second of exhalation. FVC is the total volume expired forcefully with greatest 
speed and force after maximum inspiration.  FEV1% is the FEV1 expressed as 
percentage of FVC. PEFR is the maximum velocity with which air is forced 
out of the airways during forced expiration. 
 
ASTHMA TREATMENT AND MANAGEMENT: 
                             There is no cure for asthma. The symptoms can be 
controlled with effective asthma treatment and management. Inhaled 
corticosteroids are taken daily to control the disease. Some inhalers contain 
both corticosteroid and a long-acting beta-agonist (LABA). 
 
                              LABAs control symptom and help in opening the airways15. 
Agents that block synthesis of leukotrines or their cysLT1 receptors are also 
used in the treatment of asthma.  
                     
                              Quick-relief medications are short-acting beta-agonists. 
Quick-relief medications do not control the disease.  They are used to relax 
and open the airways and relieve symptoms during an asthma severity and are 
taken before exercise in asthma15. 
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                             Acute asthma flare-ups or severe symptoms need both oral 
and intravenous corticosteroids. Proper treatment and management plan for 
asthma can reduce the symptoms and lead a better quality of life. 
 
 
COMPLICATIONS OF ASTHMA  
                           In the person with bronchial asthma from the childhood have 
certain developmental   changes in the thorax because they need some extra 
effort to breathe.  The sternum goes in and the ribs get lifted upward and 
forward called the pigeon chest.  
 
                            In the status asthmaticus the patient fails to respond to the 
usual line of treatment. It is seen in chronic asthma patients. It is a life 
threatening complication and immediate hospitalization and emergency 
treatment is required.  
 
AUTONOMIC NERVOUS SYSTEM AND ASTHMA: 
                             The nervous system is the cornerstone to our ability to 
perceive, adapt to, and interact with the world around us. Part of this system is 
called the autonomic nervous system (ANS).   
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                            ANS regulates the activity of smooth muscle, cardiac muscle 
and certain glands16.  ANS is a specific motor output portion of peripheral 
nervous system. ANS maintains internal homeostasis. Functions of ANS are 
studied by invasive and non invasive tests. Functions of ANS are affected by 
various factors. 
                    
                               Smooth muscles are present in the blood vessels and 
airways and line the tracts leading to outside of our body.                                 
The autonomic nervous system divides into two parts: the sympathetic nervous 
system and the parasympathetic nervous system.  
 
                                The bronchioles and bronchi are innervated by ANS. 
Vagal stimulation causes bronchoconstriction and it is mediated by muscuranic 
receptors in bronchial tree. Sympathetic stimulation causes bronchodilatation 
and it is mediated by β2 receptors in bronchial epithelium and smooth muscle.     
          
                               In normal airways, the breathing is due to normal ANS 
function. In asthmatic airways, there is sometimes an imbalance favoring the 
parasympathetic system and it produces constriction of the airways and 
increased mucus secretion17.  
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                               Sympathetic system increases the heart as a pump whereas 
parasympathetic stimulation decreases heart pumping allowing the heart to 
rest. Sympathetic stimulation increases overall activity of heart. This is 
accomplished by increasing both rate and force of contraction. 
Parasympathetic stimulation causes mainly opposite effects- decreased heart 
rate and strength of contraction18. VIP mediates dilatation of bronchi. Total 
airway resistance also plays a part in asthma. 
 
HISTORY OF HEART RATE VARIABILITY: 
                                The science of heart rate variability (HRV) was first 
identified in 1960’s. HRV has wide use in cardiology. For the past 20 years, 
this technique has numerous studies and updates.  
 
                                 HRV provides knowledge about alteration in autonomic 
nervous system. HRV measurements exactly pinpoint sympathetic profile of 
an individual19. 
 
                                In 1965, Hon and Lee20 noted that there was an alteration 
in the interbeat intervals during fetal distress before any change occurred in 
heart rate itself.  
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                               Heart rate variability is a measure of the balance between 
sympathetic mediators and parasympathetic mediators of heart rate. 
Epinephrine and nor epinephrine are released from sympathetic nerve fibers. 
They act on the sino-atrial and atrio-ventricular nodes and increase the rate of 
cardiac contraction and facilitate conduction at the atrio-ventricular node. 
 
                             Parasympathetic mediators of heart rate that is, the influence 
of acetylcholine released by the parasympathetic nerve fibers acting on the 
sino-atrial and atrio-ventricular nodes leading to a decrease in the heart rate 
and a slowing of conduction at the atrio-ventricular node21. 
 
                             Sympathetic mediators exert influence over longer time 
periods and are reflected in the low frequency power (LFP) of the HRV 
spectrum.  
 
                              Vagal mediators exert their influence more quickly on the 
heart and principally affect the high frequency power (HFP) of the HRV 
spectrum (between 0.15Hz and 0.4 Hz). Thus at any point in time the LFP: 
HFP ratio represents the sympathovagal balance21.  
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HEART RATE VARIABILITY  
                         Heart rate variability has been established as a tool to study 
cardiac autonomic activity. The lower frequencies (LF) and higher frequencies 
(HF) of HRV have a stronger association to sympathetic activity and vagal 
outflow respectively22.   
                   
 
                                       Heart rate variability is the cardiac beat to beat variation. It is a 
physiological phenomenon occurs due to variation in cardiac activity during 
respiration23. 
 
                       
    The heart rate and its beat to beat variation depend on SA node 
discharge which is influenced by autonomic activities.HRV is the most 
sensitive indicator of autonomic function mainly for sympathovagal balance.  
 
                           HRV provide data about the death in subjects with and 
without heart disease. There is no specific treatment available to improve the 
prognosis for patients with abnormal HRV24. A variety of linear, nonlinear, 
periodical and oscillation patterns are present in heart rate fluctuation.  
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                            HRV parameters can be analyzed in time and frequency 
domain methods. Time domain is easier to assess but finer variations are not 
better appreciated. The frequency domain measures distribution of magnitude 
of variation in different frequency bands in the frequency of 0.0-0.4 Hz.  
                              HF (high frequency) is due to vagal stimulation during 
respiration and is used as an index for vagal modulation. On giving atropine or 
by doing vagotomy respiratory sinus arrhythmia can be abolished. The heart 
rate fluctuation during respiration is due to central inhibition of vagus. 
                           
                              LF components of HRV has oscillatory pattern with 
intervals of 10 seconds. It is commonly associated with fluctuation in blood 
pressure.VLF component changes heart rate due to thermoregulation and 
humoral and local factors25. 
 
                             Power spectral analysis of HRV is done by Fast Fourier 
Transform (FFT) and auto regressive (AR) modeling. FFT is a non parametric 
method and is used in voice analysis and vibration study analysis of short term 
HRV.  
 
 17 
 
                              AR modeling is the parametric method and is the 
combination of auto regressive identification with power spectral estimation. 
Both FFT and AR modeling estimate the power spectral signals. The spectral 
components of frequency domain measures are total power (TP), low 
frequency (LF), high frequency (HF) and very low frequency (VLF). Ultra LF 
is seen in long term recordings. 
 
                          Time domain methods measure variation in heart rate and 
determine the interval between successive normal complexes. Simple time 
domain variables calculated are the mean NN interval, the mean heart rate, the 
difference between the shortest and longest NN interval and the difference 
between night and day heart rate. 
 
                          Statistical methods are used for cyclic intervals recorded for 
24 hours. They include the parameters derived from direct measurements of 
NN intervals and parameters derived from difference between NN intervals. 
These measurements determine high frequency variation in heart rate.  
 
                         Geometrical methods measure sample density distribution 
using Lorenz plot of NN or RR intervals. HRV triangular index measurement 
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is the integral of the density distribution divided by maximum of the density 
distribution. This method depends on both number and quality of NN intervals. 
 
There are two types of HRV recordings, 
• Short term 5 minutes HRV recording 
• Day night long term HRV recording 
 
                          HRV is used to assess cardio respiratory control systems. The 
artifacts and the abnormal heart beats recorded are removed before analysis. 
HF component of HRV indicates vagal tone and LF component of HRV 
indicates sympathetic tone. LF/HF ratio assesses sympathovagal balance. The 
peripheral vascular resistance exhibits intrinsic oscillation with low frequency 
and this oscillation can be influenced by thermoregulation.  
 
                           VLF and TP power represent the sympathetic tone. VLF also 
represents humoral and thermoregulatory effects and also negative emotions 
and worries. The analysis of all HRV datas is essential for clinical evaluation. 
HRV data depends on various factors. HRV obtained from normal healthy 
individuals are considered as reference and used for diagnostic purposes.  
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CLINICAL APPLICATIONS OF HRV 
• Decreased HRV is observed in cardiovascular diseases. 
• Alterations are observed in HRV before the onset of symptoms in 
cardiac disease. 
• It is used as prognostic stool in post myocardial infarction and cardiac 
transplantation. 
• It is used in the surveillance of post infarction and diabetic patients. 
• Gives information about autonomic balance. 
• It is used to determine the susceptibility to develop autonomic 
dysfunction like hypertension. 
• Decreased HRV is correlated with risk for sudden cardiac death in 
heart patients. 
• During interventions like exercise and yoga, HRV is altered. 
 
  
 
 
 
 
 
AIM AND OBJECTIVES
 20 
 
AIM AND OBJECTIVES 
 
AIM           
         The aim of our study is to investigate the autonomic imbalance in 
bronchial asthma patients using spectral analysis of heart rate variability 
(HRV).  
 
 OBJECTIVES 
• To compare HRV of bronchial asthma patients and normal volunteers. 
• To assess the cardiovascular risk in bronchial asthma patients using 
HRV. 
• To do correlation analysis between HRV parameters and PFT among 
bronchial asthma patients.
  
 
 
 
 
 
REVIEW OF 
LITERATURE
 21 
 
REVIEW OF LITERATURE 
 
ASTHMA               
 
                              The partial obstruction of bronchioles due to spastic 
contraction of the smooth muscles that result in extreme difficulty in breathing 
is called bronchial asthma. 3 to 5 % of human population contracts this 
condition at some point in their life time. The hyper sensitivity to foreign 
agents which result in bronchiolar contraction is the most common cause 
known26.  
 
                             Younger population contracts this disease due to allergic 
hypersensitivity. Pollen grains of the plants are the major source which 
constitutes the allergens. Older population is susceptible to irritants in the air. 
 
                              In the allergic type of asthma, the formation of extremely 
abundant quantities of IgE antibodies produces hypersensitive reactions due to 
antigen antibody complex when they contract specific allergens. These IgE 
antibodies in question are attached to the lung interstitial mast cells.      
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                            The person who has bronchial asthma and has already 
developed IgE antibodies to the pollen inhales the allergen, it reacts with the 
antibodies which are attached to the mast cells in the lung interstitium. These 
mast cells inturn are made to release histamine, bradykinin, eosinophilic 
chemotactic factor, leukotrines, etc. These three substances i.e., leukotrines, 
eosinophilic chemotactic factor and bradykinin constitute slow reacting 
substance of anaphylaxis. 
 
                            Thus released substances result in edematous changes in the 
bronchiolar walls. This localized reaction induces thick mucus secretion and 
smooth muscle spasm in the bronchioles. Outcome of these events is the 
airway obstruction due to increased resistance. 
  
                            The diameter of the bronchiolar lumen in bronchial asthma is 
less during expiration than inspiration, because bronchiolar collapse during 
expiratory effort compresses the bronchioles.  
 
                              In a person with bronchial asthma inspiration is less taxing 
but the real difficulty comes in expiration. When the lung volumes are 
measured clinically the maximum expiratory rate is severely reduced and the 
timed expiratory volume is also affected resulting in breathlessness.                              
 23 
 
                              In an asthmatic episode the residual volume of the lung is 
enhanced so does the functional residual capacity. The thoracic cavity bulges 
resulting in permanent enlargement. This condition is called barrel chest26. 
 
CARDIAC ASTHMA 
                                When the person with congestive cardiac failure has 
wheezing, coughing and shortness of breath, cardiac asthma is the likely 
diagnosis. The symptoms of cardiac asthma resembles bronchial asthma hence 
the name.  
 
                                Cardiac asthma may be symptom of acute heart failure 
leading to pulmonary edema. It is very important to differentiate two types of 
asthma because the treatment of bronchial asthma could worsen cardiac 
asthma and leads to severe arrhythmias27.  
 
ATOPIC ASTHMA 
                               Atopic asthma is characterized by chronic inflammation of 
the bronchial mucosa in which eosinophils and immunoglobulin (Ig)-E 
dependent mechanism is prominent.  
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                            The specific proeosinophilic mediator interleukin (IL)-5 and 
essential cofactor for IgE in B-lymphocytes play important role in atopic 
asthma and determine asthma clinical expression and severity which lead to 
development of interleukin targeted therapies28.  
 
                             Acupuncture is the most common treatment most population 
believes and it improves the pulmonary functions of the asthmatics with 
different state of disease29. 
 
AUTONOMIC NERVOUS SYSTEM:                       
                             ANS controls emotional responses of the body and 
responses to environment that occur without conscious knowledge. The 
striking characteristics of ANS are the rapidity and the intensity with which it 
changes the visceral functions. 
 
                             The term “autonomic” is derived from the words auto and 
nomos. The meaning of auto is ‘self’ and nomos is ‘control’. The ANS 
controls functions of the involuntary organs of the body that includes heart, 
blood vessels, exocrine, endocrine glands and visceral organs30. 
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                               The ANS is activated mainly by centers located in spinal 
cord, brainstem and hypothalamus. Cortical areas controlling functions of 
ANS are mainly limbic cortex and prefrontal cortex and the sympathetic 
response to emotion originates in these areas. 
 
FUNCTIONS OF ANS 
                    The five important functions of ANS are   
• Homeostasis maintenance in the body 
• Visceral activities regulation  
• Smoothens body response  
• Coordination of body response 
• Assistance to endocrine system      
                   
DIVISIONS OF ANS 
                          Sympathetic nervous system and parasympathetic nervous 
system are two branches of ANS. Enteric nervous system is considered as third 
division of ANS. Sympathetic division acts during stress responses i.e., flight 
or fight reactions and it is considered as the accelerator. The parasympathetic 
division of ANS functions during resting conditions and acts as the brake. 
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                           Sympathetic system helps the body to face and overcome 
critical situations in life. It helps in regulation of blood pressure, respiration, 
and metabolism. The cell bodies of sympathetic system are located in the 
intermediolateral grey horn first thoracic to 3rd or 4th lumbar segments of spinal 
cord and sympathetic ganglia close to vertebral column. Hence it is called as 
thoracolumbar division of the ANS31.       
                           
                          The parasympathetic system works by the side of the 
sympathetic system. It checks the over activity of sympathetic system and 
smoothens the autonomic responses. It is called as craniosacral division of 
ANS because of its cell bodies location in the cranial nuclei in the brainstem 
and sacral region of spinal cord. 
 
                            In most organs both these systems are activated in a 
reciprocal fashion i.e. when the discharge rate in one division is increased, the 
rate of discharge in other division is decreased. In some organs both division 
of ANS work synergistically like in stomach parasympathetic division 
increases the gastric secretion, simultaneous sympathetic activation causes 
increased mucus secretion. 
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                           Enteric nervous system is located within the walls of digestive 
tract. Two organized nerve plexus of this system are myentric plexus in 
between muscular coats involves in control of digestive tract motility and 
submucus plexus in submucus layer which regulates gastrointestinal blood 
flow32. 
 
NEUROTRANSMITTERS OF ANS 
                             Preganglionic cholinergic sympathetic fibers secrete 
acetylcholine while postganglionic adrenergic sympathetic fibers secrete 
adrenaline and noradrenaline. Parasympathetic division secretes acetylcholine 
in both pre ganglionic and post ganglionic fibers. 
 
HYPOTHALAMUS AND ANS  
                           Hypothalamus has projections to the parasympathetic vagal 
nuclei and neurons in the medulla. Medulla has a group of nerve fibers which 
descend to the sympathetic nervous system in the spinal cord. Because of these 
connections, hypothalamus controls the heart rate, cardiac functions and 
vasoconstriction. 
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                           Hypothalamus integrates somatosensory, endocrine and 
autonomic responses that are essential components of homeostasis 
mechanisms during stressful conditions. Because of its influence on ANS, 
Sherrington pointed out that hypothalamus is the ‘head-ganglion’ of autonomic 
nervous system33.  
 
AUTONOMIC NERVOUS SYSTEM AND ASTHMA:   
                                 Parasympathetic nervous system when stimulated 
constricts the bronchioles, where as the sympathetic nervous system relaxes. In 
bronchial asthma there is an autonomic imbalance where the parasympathetic 
nervous system takes the upper hand. This invariably results in the constriction 
of airways17.  
 
                               The dominant hand played by the parasympathetic nervous 
system induces acetylcholine release from the nerve endings. This inturn acts 
on the postjunctional muscarinic receptors located on the smooth muscle and 
submucosal glands of the airways and cause constriction of bronchioles and 
excess mucus secretion18. 
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ASTHMA AND CARDIOVASCULAR DISEASE 
                              Paul L.Enright et al in their study found that 6% of people 
with cardiovascular diseases (CVD) or risks had previous history of asthma 
and 30% of them were taking asthma medications. They found people who 
were asthmatics with congestive heart failure had higher level of high density 
lipoprotein (HDL) cholesterol and plasma fibrinogen levels34.  
 
                            Michela Bellocchia et al in their study on predictors of 
cardiovascular disease in asthma and chronic obstructive pulmonary diseases 
(COPD) indicated that CVD are frequent in patients with chronic obstructive 
disorders and their strongest predictors were age and airway obstruction. They 
found the prevalence of pressure overload and volume overload were similar 
in both asthma and COPD35. 
 
                             Carlos Iribarren et al in their study on asthma in the older 
population found people with coronary heart disease, cerebrovascular disease 
and heart failure had bronchial asthma history particularly in women. They 
found asthmatics on corticosteroid medications were at risk of developing 
CVD36.  
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SPIROMETRY  
                            Spirometry is the most common procedure used to assess the 
ventilatory functions of lung as a function of time. It is the screening test for 
general respiratory health. The person subjected to spirometry need to give 
their maximum effort. This test is used to identify the obstructive and the 
restrictive ventilation patterns.  
 
      
           
HISTORY OF SPIROMETRY  
                            The history of concept of spirometer started with Roman 
Empire. Claudius Galen, the Greek doctor performed the lung function test by 
asking a boy to breath in and out of the bladder37. 
 
                            Air volumes of the lungs were measured by J.Jurin and he 
had given absolute volumes. Tidal volume of 600 ml and maximal expiration 
of 3610 ml were measured. The principles of Archimedes were used in doing 
this procedure with help of the bladder and were asked blow into it37. 
 
                           At the beginning of 19th century, Sir Humphry Davy 
measured his own volumes and capacities with the help of a gasometer. He 
 31 
 
used hydrogen dilution method to measure residual volume but now helium is 
used instead of hydrogen.  
 
                          Gasometer was a complex instrument with a counter weight to 
balance. Sir Humphry Davy was the first person to estimate his own oxygen 
consumption and carbon-dioxide (CO2) liberation 38.  
 
                          E.Kentish and Charles Turner used pulmometer to measure 
ventilatory volumes and the power of expiratory muscles. Karl Von Vierordt 
used expirator to measure lung volumes by focusing exhaled gases and found 
exact determinants of volumetric parameters39. 
 
                         John Hutchinson was the first to invent spirometer which 
captures exhaled air from the lungs and measure vital capacity. Wintrich 
developed a spirometer which was easier to use. He found that body weight, 
height and age determine vital capacity40.  
 
                         The portable spirometer was made by E.Smith and with this 
gas metabolism was quantified by Him. A kymograph was added to the 
spirometer by Salter and recorded the time in relation to ventilatory volumes. 
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                         Ergospirometery, Pneutachygraphic spirometer, vitallograph 
and Jaeger spirometer were also used to measure ventilatory volumes. Modern 
spirometry has closed circuit and open circuit methods.  
 
                          The person breathes into a container which was already filled 
and through soda lime tower the exhaled air passes which absorbs CO2 and 
oxygen goes back into the container in the closed circuit method. The energy 
expenditure could not be measured during physical activity by closed circuit 
method41. 
 
                          The person breathes air from outside and expired air enters 
into a gasometer. The expired air is measured and analyzed. It is useful during 
physical activity to measure the loss of the energy.     
 
                         There are three open circuit methods. In portable spirometry 
expired air passes through gasometer which was analyzed and oxygen 
consumption determined. In the bag technique the expired air was collected in 
the canvas bag or the rubber balloon41. 
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                        In the computerized spirometry the expired air of the subject is 
continuously sampled. There is flow measuring device to record air flow. The 
expired gas mixture composition is analyzed for oxygen and carbon dioxide. 
 
HEART RATE VARIABILITY 
                           Heart Rate Variability has emerged as the most common tool 
to assess sympathovagal balance in humans either for research or for clinical 
studies.  
 
                          There are more publications on HRV during past ten years.                           
HRV is the interval between two R waves. More the variability between RR 
intervals more healthy is the heart functioning. 
 
                         There is an association between death due to cardiac cause 
with increase in sympathetic and decrease in parasympathetic activity. This 
has emerged as useful marker in identifying the autonomic dysfunction.  
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                         HRV is one of the most important markers of sympathetic 
balance. Other names for HRV are Cycle Length Variability, RR Variability 
and RR interval tachogram. HRV is the most commonly used term23. 
 
HISTORY OF HRV 
                          In 1965, Hon and Lee gave appreciation for HRV and its 
clinical relevance and noted that there was alterations in the interbeat intervals 
during fetal distress before any change occurred in heart rate itself20.  
                                                     
 
                         The clinical importance of HRV became appreciated in the late 
1980s, when it was confirmed that HRV was a strong and independent 
predictor of mortality after an acute myocardial infarction.  
 
                                        With the availability of new, digital, high-frequency, 24-hour, 
multichannel ECG recorders, 5 min, HRV has the potential to provide 
additional valuable insight into physiological and pathological conditions and 
to enhance risk stratification42. 
 
                          The theory based on the role of HRV in understanding the 
nature of vagal outflow to the heart decomposes HRV based on frequency 
 35 
 
domain with an emphasis on respiratory sinus arrhythmia and its transmission 
by a neural pathway that is distinct from other components of HRV. 
 
 
PHYSIOLOGICAL BASIS OF HRV 
 
                        Heart rate variability has been established as a tool to study 
cardiac autonomic activity. The lower frequencies (LF) and higher frequencies 
(HF) of HRV have a stronger association to sympathetic activity and vagal 
outflow respectively43.          
                    
 
                                     Heart rate variability is the cardiac beat to beat variation. It is a 
physiological phenomenon occurs due to variation in cardiac activity during 
respiration23. 
 
                       
    The heart rate and its beat to beat variation depend on SA node 
discharge which is influenced by autonomic activities.HRV is the most 
sensitive indicator of autonomic function mainly for sympathovagal balance.  
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                           HRV provide data about the death in subjects with and 
without heart disease. There is no specific treatment available to improve the 
prognosis for patients with abnormal HRV24. A variety of linear, nonlinear, 
periodical and oscillation patterns are present in heart rate fluctuation.  
 
                          HRV parameters can be analyzed in time and frequency 
domain methods. Time domain is easier to assess but finer variations are not 
better appreciated. The frequency domain measures distribution of magnitude 
of variation in different frequency bands in the frequency spectrum of 0.0-0.4 
Hz.  
 
                         HF (high frequency) is due to vagal stimulation during 
respiration and is used as an index for vagal modulation. On giving atropine or 
by doing vagotomy respiratory sinus arrhythmia can be abolished. The heart 
rate fluctuation during respiration is due to central inhibition of vagal tone.  
 
                          LF components of HRV has oscillatory pattern with intervals 
of 10 seconds. It is commonly associated with fluctuation in blood 
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pressure.VLF component changes heart rate due to thermoregulation and 
humoral and local factors25. 
 
                         Power spectral analysis of HRV is done by Fast Fourier 
Transform (FFT) and auto regressive (AR) modeling. FFT is a non parametric 
method and is used in voice analysis and vibration study analysis of short term 
HRV.  
 
                          AR modeling is the parametric method and is the combination 
of auto regressive identification with power spectral estimation. Both FFT and 
AR modeling estimate the power spectral signals. The spectral components of 
frequency domain measures are total power (TP), low frequency (LF), high 
frequency (HF) and very low frequency (VLF). Ultra LF is seen in long term 
recordings. 
 
                          Time domain methods measure variation in heart rate and 
determine the interval between successive normal complexes. Simple time 
domain variables calculated are the mean NN interval, the mean heart rate, the 
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difference between the shortest and longest NN interval and the difference 
between night and day heart rate. 
 
                          Statistical methods are used for cyclic intervals recorded for 
24 hours. They include the parameters derived from direct measurements of 
NN intervals and parameters derived from difference between NN intervals. 
These measurements determine high frequency variation in heart rate.  
 
                         Geometrical methods measure sample density distribution 
using Lorenz plot of NN or RR intervals. HRV triangular index measurement 
is the integral of the density distribution divided by maximum of the density 
distribution. This method depends on both number and quality of NN intervals.  
There are two types of HRV recordings, 
• Short term 5 minutes HRV recording 
• Day night long term HRV recording 
 
                         HRV is used to assess cardio respiratory control systems. The 
artifacts and the abnormal heart beats recorded were removed before analysis. 
HF component of HRV indicates vagal tone and LF component of HRV 
indicates sympathetic tone.  
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                          LF/HF ratio assesses sympathovagal balance. The peripheral 
vascular resistance exhibits intrinsic oscillation with low frequency and this 
oscillation can be influenced by thermoregulation.  
 
                           VLF and TP power represent the sympathetic tone. VLF also 
represents humoral and thermoregulatory effects and also negative emotions 
and worries. The analysis of all HRV datas is essential for clinical evaluation. 
HRV data depends on various factors. HRV obtained from normal healthy 
individuals are considered as reference and used for diagnostic purposes44.               
 
HRV AND ASTHMA     
                             Kuzma N et al, in the study of seasonal variation in HRV in 
asthmatic children found that the environmental changes during different 
seasons increase the symptoms in the asthmatics. HRV of the asthmatic 
children is more susceptible to seasonal changes. They found there was 
seasonal variation in high frequency (HF), low frequency (LF) and LF/HF 
ratio of the HRV components which have been used as an index for autonomic 
functions45. 
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                               Domnik NJ, et al, in their study of induced hyper 
responsiveness altered HRV and body temperature found that there was an 
altered autonomic tone in chronic respiratory diseases and suggested it as an 
important factor in cardiovascular co-morbidities. They also found mild 
allergic sensitization in asthma was associated with reduced HRV46.       
  
                                Lutfi MF et al, in their study of autonomic modulation in 
patients with bronchial asthma based on short term HRV said that the level of 
asthma control correlate positively with normalized LF and LF / HF ratio and 
negatively with normalized HF of HRV. They found duration of asthma 
correlates positively with HF norm and negatively with LF norm. They 
concluded poor asthma management is associated with lower HRV, depressed 
sympathetic tone and enhanced parasympathetic effect especially with longer 
asthma duration47. 
 
                                Sekerel BE, et al the study of effects of inhaled formeterol 
on ANS in adolescents with asthma found that inhalation of single dose 
formeterol increased heart rate and decreased HRV during first 12 hours and 
concluded that there was decreased cardiovagal responsiveness and increased 
sympathetic tone in cardiac autonomic control48.                                 
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                                Chen SR et al, in their study of the influence of physical 
activity level on HRV among asthmatics found that total power, LF, LF norm 
and LF/HF ratio of HRV parameters were significantly low in asthmatics 
compared to healthy adults both in the resting condition and during physical 
activity. They found that physical activity had positive relationship with LF 
norm and negative relationship with HF norm in asthmatics. They suggested 
engaging asthmatics with moderate physical activity improves HRV49. 
 
                                 Campbell TS et al, in their study on asthma self-efficacy, 
high frequency HRV and negative effect in daily life of the asthma, suggested 
that severe asthma was associated with increased parasympathetic activity and 
airflow obstruction. They suggested physical activity was associated with 
decreased levels of high frequency HRV in asthmatics50. 
 
                                  Du J, et al in the study of HRV in asthma showed that in 
asthma subjects the vagal tone were increased and sympathetic tone were 
decreased compared to that of normal persons. They suggested autonomic 
nervous function of asthmatic differ from young adults even in the normal 
conditions51. 
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                                 Korematasu S, et al in their study of auto regressive 
analysis of HRV and blood pressure (BP) in asthmatic children found 
parasympathetic nervous system disorder in severe asthmatics and concluded 
that the spectral analysis of HRV and BP are the useful tool for quantifying 
ANS activity52.     
 
                                Mitsunori Murata, et al in their study of HRV during 24 
hours in asthmatic children found that the autonomic nervous functions in 
asthmatics were decreased and said that severity of asthma had significant 
effects on HRV. They also suggested that autonomic functions in asthmatic 
differ from normal subjects even when they were free from asthma attacks53.       
 
                                Gupta J, et al in the study of HRV in bronchial asthma 
found normalized LF component was significantly reduced while normalized 
HF component was significantly increased in asthmatics. They concluded there 
was significant rise in vagal outflow and decreased sympathetic effects in 
asthmatics and this may be the patho-physiological mechanism for airway 
obstruction in bronchial asthma54. 
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                                  Gomes EL, et al in the study of autonomic modulation 
during maximal and sub maximal work rate and functional capacity in 
asthmatic children suggested that there was no withdrawal of parasympathetic 
cardiac modulations after maximum exercise while the functional capacity and 
lung function vary depending on the degree of the inflammation of the airways 
in the asthmatics55. 
 
                                    Emin O56, et al in their study on ANS dysfunction and 
atopic asthma disease severity in younger population found ANS dysfunction 
varied significantly among mild, moderate and severe asthmatics. They found 
HRV and sympathetic skin response provide platform for assessing the 
severity of asthma in the younger age groups. 
 
                                    Ostrowska Nawarycz L et al, in their study of HRV 
analysis in younger population with bronchial asthma confirmed that there was 
significant association between the vagal activity and frequency and intensity 
of bronchial asthma in children and youth and insisted short term HRV could 
be used to assess autonomic function in these people57.  
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                                   Jartii TT et al, in the study of cardiovascular autonomic 
functions of cardiovascular system in asthmatic children by spectral analysis of 
HRV and B.P found alterations in systolic B.P and an increase in sympathetic 
functions in CVS of the children with asthma58.  
                                
                                    
                                   Garrard CS et al, in the study of spectral analysis of 
HRV in bronchial asthma found that acute asthmatics had higher heart rates 
and HRV due to sympathetic mediation compared to that of normal subjects59.             
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MATERIALS AND METHODS 
 
                  This study was done in the department of Physiology, PSG 
IMS&R. Institutional Human Ethics Committee ethical clearance and 
informed written consent from the cases and controls were obtained before the 
study. 
 
This was an observational type of study. 
30 cases and 30 controls were included in the study. 
 
                 The cases were persons having bronchial asthma in the age group 
between 20 to 45 years. The cases were selected from pulmonology OPD and 
respiratory medicine OPD according to the inclusion criteria.  
 
                 Details of present history, treatment history were obtained. The 
controls were normal healthy volunteers in the same age group. General 
examinations including height in cms and weight in kgs were recorded.  
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INCLUSION CRITERIA:  
• Physician diagnosed asthmatics as cases. 
• Age between 20-45 years includes both men and women. 
• Normal persons willing to participate in the study as controls. 
 
EXCLUSION CRITERIA: 
• Smokers 
• Alcoholics 
• Hypertensive patients 
• Diabetic patients  
• Patients with thyroid disorders 
• Ischemic heart disease & myocardial infarction patients  
• Patients with lung cancer and restrictive lung diseases  
• Pregnancy 
• Patients on drugs known to influence HRV within 24hrs prior to 
recruitment. 
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                     The DATA collection tool is a protocol that has patient data, 
history, physical examination findings and investigation details which is 
attached in annexure. The subjects who fulfilled the criteria were taken for 
ECG recording for HRV analysis in the Physiology research laboratory, and 
pulmonary function tests in the PFT laboratory, PSG IMS&R. 
 
PULMONARY FUNCTION TESTS 
                      PFTs are employed to assess the ventilation, diffusion and 
perfusion of the lungs. Ventilatory function measures lung size, patency of 
airways and alveolar ventilation. PFTs are employed to reach a diagnosis, to 
follow the progression of the disease and the effectiveness of treatment, to 
assess respiratory status and to assess physical fitness. 
 
SPIROMETRY  
                    PFT is the non invasive physiological test. Spirometry is the most 
common laboratory procedure used to assess the ventilatory functions of lung 
as a function of time. It is the screening test for general respiratory health.  
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                          Premedication test was done for both cases and controls. 
Those persons having normal PFT values were taken as controls. Post 
medication test was done after giving asthalin (salbutamol 400mcg) nebulizer 
and rest for about 30 min in the cases. Those persons who had reversibility of 
FEV1 by more than 12% were diagnosed as asthmatics and they were included 
in the study.  
 
                          While performing spirometry, the subject must give his 
maximum effort. The procedure was carefully and clearly explained to cases 
and controls and actively motivated to perform maximally. During spirometry 
the subjects were asked to sit in a chair straight and both sole touching the 
floor flat. The procedure needs time to get the maximum effect. 
 
                         The two obstructive and restrictive abnormal ventilation 
patterns are identified using spirogram. Obstructive patterns are one which 
affects the rate at which air can be expelled from the lungs and is characterized 
by a reduced forced expiratory volume in first second (FEV1), normal or 
reduced forced vital capacity (FVC) and a low FEV1%.   
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                                 The FEV1% of <70% is diagnostic of air flow obstruction and 
confirms obstructive disease. Restrictive pattern affects lung expansion. FEV1 
and FVC are decreased, leaving a normal ratio of   FEV1/FVC.  
 
THE INSTRUCTIONS GIVEN TO THE SUBJECTS DURING THE 
PROCEDURE: 
• Seal the lips and teeth tightly around the mouthpiece. 
• Breathe in fully so the lungs must be completely full. 
• Nose clips are applied to the nose. 
• Blow the air out as fast as possible for minimum of 6 seconds with 
maximal effort. 
• Breath in fully again without removing the mouthpiece from the mouth. 
 
                         The controls and cases were asked to do the spirometry thrice 
and the best of the three readings was included for the study. Spiropalm-digital 
airflow spirometry which senses air current connected to a computer is used to 
assess pulmonary function tests. The variables of PFTs taken in the study are 
forced vital capacity (FVC), forced expiratory volume in first second (FEV1), 
FEV1%, Peak expiratory flow rate (PEFR) and FEF25-75%. 
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• FORCED VITAL CAPACITY  
                 FVC is the largest amount of air that can be expired after a 
maximal inspiration.  
                 It is an index for pulmonary function and assesses the 
strength of the respiratory muscle. 
• FORCED EXPIRATORY VOLUME IN FIRST SECOND 
               FEV1 is the fraction of vital capacity expired during the first 
second of a forced expiration.  
              It is decreased in asthma. 
• FORCED EXPIRATORY VOLUME IN FIRST SECOND 
PERCENT  
              FEV1% = FEV1/FVC x 100 
             Normal is 80%. It is useful to differentiate obstructive and 
restrictive disease. 
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• PEAK EXPIRATORY FLOW RATE  
                   It is the maximum flow rate of air during a single forced 
expiration.  
                   It is useful in distinguishing reversible and irreversible lung 
diseases. 
• FEF25-75%: 
             This is the flow rate between 25% and 75% 0f FVC.  
            It is useful for detecting the response of the bronchodilator in the 
asthmatics 
 
ECG RECORDING AND HRV ANALYSIS 
                  HRV is a non-invasive procedure. Electrocardiograph was done for 
5 minutes in a computerized physiograph (NEVIQURE- Digital ECG 
recorder) in Lead 2. HRV analysis was done using Finland software. 
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ECG RECORDING 
                           After getting written informed consent for ECG recording all 
the study subjects were enrolled. To avoid anxiety the subjects were asked to 
sit silently for few minutes before the procedure in Physiology laboratory. 
ECG recording was done in supine position by using computerized 
physiograph in Lead II for a period of 5 minutes with the use of adhesion 
electrodes in both wrist and legs. 
 
                         The left arm was connected with positive electrode, right arm 
with negative electrode, left foot with reference electrode and right foot with 
ground electrode. Baseline ECG recording were obtained from all the subjects 
and abnormal baseline ECG were excluded.  
 
                          RR intervals were recorded after clearance of noise and 
baseline fluctuations by digital filters. Subjects with ectopic beats were 
excluded from the study. Resting heart rate was recorded. All the data were 
filtered by using a digital notch filters with a sampling of 1000 samples/sec. 
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                         The inbuilt software select the RR peaks and these RR 
intervals which were recorded as time points were then introduced into a 
Microsoft excel sheet and RR intervals were copied to a notepad file. 
 
                          The resting autonomic activity was assessed by HRV. Two 
types of parameters are determined by HRV analysis which includes,  
1. Time Domain parameters 
2. Frequency Domain parameters. 
 
THE TIME DOMAIN PARAMETERS: 
                          The Time Domain parameters are based on statistical 
operations on R-R intervals. Mean RR (NN), standard deviation of all NN 
intervals (SDNN), the square root of the mean squared difference of successive 
NNs (RMSSD), PNN50-the proportions of NN50 divided by total number of 
NNs and NN50 are the parameters. They are used to distinguish two different 
HRV indices.  
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• Mean RR (NN): 
              This is the average of all NN intervals. It indicates 
sympathovagal function because it is inversely proportional to mean 
heart rate at a given physiological state.  
              It is also called as normal to normal intervals. 
 
• SDNN 
             It is the standard deviation of all NN intervals. This is a measure 
of total variability.  
             It reflects HRV in low and high frequency ranges, when 
considered for a short period of time. 
 
 
• NN50 count: 
             This estimates high frequency variation in heart rate.  
             It is the number of pairs of adjacent NN intervals differing more 
than 50 ms in the entire recording. 
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• pNN50 
         It is the proportion derived by dividing NN50 by total number of 
NN intervals. This estimates high frequency variation in heart rate along 
with NN50 count. 
 
 
• RMSSD 
        It is the square root of the mean of the sum of the squares of 
differences between adjacent NN intervals. This also estimates high 
frequency variations in heart rate and hence it is a measure of vagal 
response.   
 
The Frequency Domain Measures: 
                   In HRV recorded all abnormal heartbeats and artifacts were 
removed. Cardiac tachogram was resampled. The frequency domain 
parameters are LF, HF. LF nu, HF nu and LF/HF power ratio. Other 
parameters include total power and very low frequency power. 
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• Low frequency power (LF) 
             LF spectrum is in the range from 0.04 to 0.15 Hz.  
            This indicates both sympathetic and parasympathetic tone. 
 
• High frequency power (HF) 
            HF power spectrum is in the range from 0.15 to 0.4 Hz.  
            This indicates vagal tone. 
 
• LF norm (nu)  
         It is low frequency power in normalized units.  
         LF norm = LF/ (Total power – VLF) X100 
 
• HF norm (nu)   
        It is high frequency power in normalized units.  
        HF norm = HF/ (Total power – VLF) X100 
 
• LF/HF power ratio: 
             The LF/HF ratio is used to asses sympathovagal balance. A 
decrease in the score indicates either decrease in sympathetic tone or 
increase in parasympathetic tone. 
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                        HRV analysis was done by feeding these harmonic components 
of RR interval notepad file to HRV analysis software version 1.1 from 
Biomedical Signal Analysis group, Department of Applied Physics, University 
of Kuopio, Finland.  
 
                       Power spectral analysis was done by fast Fourier transformation, 
discovered by Jean Baptiste Joseph Fourier. 
 
STATISTICAL ANALYSIS 
                       The statistical analysis was done using SPSS software 
(statistical package for the social science version-19). By independent Students 
t’ test, analysis was done between the study group and control group.  
 
                       Both HRV and PFT values were compared, which gave the 
exact relationship between HRV and asthma. 
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                       Pearson correlation analysis was used to correlate HRV 
parameters and FEV1% and PEFR. Chi square test was used to correlate family 
history with bronchial asthma. 
 
Values were expressed as Mean ± SD.  
p > 0.05 was considered not significant. 
p ≤ 0.05 was considered statistically significant. 
p < 0.01 was considered moderately significant. 
P < 0.001 was considered highly significant. 
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RESULTS 
 
              60 subjects were included in this study. Duration of the study was for 
7 months from January to July 2014. 30 were normal subjects and 30 were 
bronchial asthmatics.  
              PFT and five minute electrocardiogram was taken for all the 60 
subjects and HRV analysis was done.              
             The PFT values were compared between the controls and cases. 
            The HRV parameters (Time domain measures and the frequency 
domain measures) were compared between the controls and cases. 
p value of < 0.05 was considered as significant. 
Group I - Controls – normal subjects. 
Group II - Cases – bronchial asthma patients. 
           Independent student t test, Pearson correlation analysis and Chi square 
test were used for statistical analysis. 
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1. BASELINE CHARACTERISTICS OF THE BRONCHIAL ASTHMA 
PATIENTS AND NORMAL SUBJECTS (Table: 2 and Chart: 1) 
Age (years) 
                  Mean age of group I (Controls) was 31.27 ± 7.08 and group II 
(cases) was 32.03 ± 8.52. This increase in mean age of the cases was not 
statistically significant with p value of 0.706   
 
Weight (kg) 
                 Mean weight of group I was 62.4 ± 12.09 and group II was 60.8 ± 
11.62.This decrease in mean weight of the cases was not statistically 
significant with p value of 0.603.  
 
Height (cm) 
                   Mean height of group I was 161.53 ± 11.07 and group II was 
162.93 ± 9.56. This increase in mean height of the cases was not statistically 
significant with p value of 0.602.   
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BMI (kg/m2) 
                Mean BMI of group I was 23.89 ± 2.85 and group II was 23.05 ± 
3.19. This decrease in mean BMI of the cases was not statistically significant 
with p value 0.282. 
 
2. COMPARISON OF PULSE AND BLOOD PRESSURE OF THE 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS (Table: 
3 and Chart: 2). 
Pulse rate (bpm) 
               Mean pulse rate of group I was 76.33 ± 7.26 and group II was 75.27 
± 5.47. This decrease in mean pulse rate of the cases was not statistically 
significant with p value 0.523. 
             
Blood pressure (mmHg) 
             Mean systolic blood pressure (SBP) of group I was 120 ± 8.7 and 
group II was 112.33 ± 9.35. This decrease in mean SBP of the cases was 
highly significant with p value < 0.01. 
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             Mean diastolic blood pressure of group I was 75 ± 9 and group II was 
73 ± 7.49. This decrease in mean diastolic blood pressure of the cases was not 
statistically significant with p value < 0.354.            
 
3. COMPARISON OF PULMONARY FUNCTION TESTS VALUES OF 
THE BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS 
FVC
 
(L) (Table: 4 and Chart: 3)             
           Mean FVC values of group I was 3.65 ± 0.82 and group II was 2.29 ± 
0.70. This decrease in mean FVC of the cases was very highly significant 
with p value < 0.001. 
 
FEV1 (L) (Table: 4 and Chart: 3)          
           Mean FEV1 values of group I was 3.11 ± 0.69 and group II was 1.56 ± 
0.59. This decrease in mean FEV1 of the cases was very highly significant     
with p value < 0.001.  
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FEV1 % (Table: 4 and Chart: 4)                     
              Mean FEV1% values of group I was 84.82 ± 1.92 and group II was 
63.74 ± 7.9. This decrease in mean FEV1% of the cases was very highly 
significant with p value < 0.001 
 
FEV25-75% (L) (Table: 5 and Chart: 3)                      
              Mean FEV25-75% values of group I was 3.43 ± 0.42 and group II was 
1.08 ± 0.5. This decrease in mean FEV25-75% of the cases was very highly 
significant with p value < 0.001 
 
 
PEFR (L/sec) (Table: 5 and Chart: 5)          
              Mean PEFR values of group I was 7.69 ± 1.25 and group II was 3.75 
± 1.79. This decrease in mean PEFR of the cases was very highly significant 
with p value < 0.001. 
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4. COMPARISON OF TIME DOMAIN MEASURES OF THE 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS  
Mean RR (sec) (Table: 6 and Chart: 6)          
              Mean of the mean RR interval of group I was 0.74 ± 0.1 and group II 
was 0.81 ± 0.13. This increase in mean of the mean RR in the cases was 
statistically significant with p value < 0.05. 
 
Mean HR (bpm) (Table: 6 and Chart: 7)          
              Mean of the mean HR of group I was 83.23 ± 8.7 and group II was 
74.73 ± 6.97. This decrease in mean of the mean HR in the cases was very 
highly significant with p value < 0.001. 
 
SDNN (ms) (Table: 7 and Chart: 8)          
          The mean SDNN of group I was 63.37 ± 27.75 and group II was 37.30 ± 
18.59. This decrease in mean SDNN of the cases was very highly significant 
with p value < 0.001. 
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RMSSD (Table: 7 and Chart: 8)          
                The mean RMSSD of group I was 51.98 ± 15.59 and group II was 
25.82 ± 9.33. This decrease in mean RMSSD of the cases was very highly 
significant with p value < 0.001. 
 
NN50 counts (Table: 7 and Chart: 9)          
                The mean NN50 counts of group I was 72.57 ± 9.96 and group II 
was 37.77 ± 6.05. This decrease in mean NN50 counts of the cases was highly 
significant with p value < 0.01. 
 
pNN50 % (Table: 7 and Chart: 9)          
          The mean pNN50% of group I was 27.06 ± 3.16 and group II was 12.90 
± 2.36. This decrease in mean pNN50% of the cases was very highly 
significant with p value < 0.001. 
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5. COMPARISON OF FREQUENCY DOMAIN MEASURES OF THE 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS 
Very Low power frequency in ms2 (Table: 8 and Chart: 10)          
                Mean VLF in ms2 of group I was 2334.23 ± 520.20 and group II 
was 1289.36 ± 285.89. This decrease in mean VLF in ms2 of the cases was 
highly significant p value < 0.01. 
 
Low power frequency in ms2 (Table: 8 and Chart: 11)          
                 Mean LF in ms2 of group I was 331.07 ± 64.27 and group II was 
199.4 ± 35.27. This decrease in mean LF in ms2 of the cases was very highly 
significant with p value < 0.001. 
 
High power frequency in ms2 (Table: 8 and Chart: 11)          
               Mean HF in ms2 of group I was 85.9 ± 11.18 and group II was 143.23 
± 25.46. This increase in mean HF in ms2 of the cases was very highly 
significant with p value < 0.001. 
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Low power frequency in normalized units (LF n.u) (Table: 9 and Chart: 12)          
              Mean LF n.u. of group I was 69.19 ± 9.72 and group II was 68.89 ± 
11.82. This decrease in mean LF n.u. of the cases was not statistically 
significant with p value 0.236.  
 
High power frequency in normalized units (HF n.u) (Table: 9 and Chart: 
13)          
             Mean HF n.u. of group I was 30.78 ± 9.72 and group II was 33.47 ± 
15.79. This increase in mean HF n.u. of the cases was not statistically 
significant with p value 0.107.  
 
LF/HF ratio (Table: 9 and Chart: 13)          
            Mean LF/HF ratio of group I was 3.85 ± 0.37 and group II was 1.66 ± 
0.24. This decrease in mean LF/HF ratio of the cases was not statistically 
significant with p value 0.108. 
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6. CORRELATION OF FAMILY HISTORY WITH ASTHMA 
                 It was done by using Chi square test. 
TABLE: 1 CHI SQUARE TEST FOR CORRELATION OF FAMILY 
HISTORY WITH BRONCHIAL ASTHMA 
 Positive family 
history of asthma 
Negative 
family history 
of asthma 
 
 
Cases 
 
           25 
 
          5 
 
Controls 
 
           3 
 
         27 
 
 Odds ratio = 25 x 27 / 3 x 5  
                   = 45. 
 
                                      This shows that those with positive family history of 
bronchial asthma have 45 times more chance of getting asthma than those with 
negative family history of bronchial asthma. 
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7. CORRELATION OF FEV1% AND PEFR WITH HRV 
PARAMETERS. 
              Correlation of FEV1% and PEFR with HRV parameters was done by 
using Pearson correlation statistical analysis. r value < 0.05 was considered 
statistically significant. 
 
Time domain measures 
                  Mean RR, Mean HR, SDNN, RMSSD, NN50 counts and 
pNN50% had no significant correlation with both FEV1% and PEFR. 
 
Frequency domain measures 
                 VLF, LF, LFnu, HFnu and LF/HF had no significant correlation 
with PEFR and FEV1%.  
HF had no significant correlation with PEFR.  
HF showed significant negative correlation with FEV1% with r value < 0.05. 
The decrease in FEV1% increases HF. 
  
 
 
 
 
 
TABLES AND CHARTS
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TABLE: 2 
COMPARISON OF AGE, WEIGHT, HEIGHT AND BMI OF 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
Age(yrs) 
Controls 31.27 ± 7.08  
0.706 NS Cases 32.03 ± 8.52 
 
Weight (kg) 
Controls 62.4 ± 12.09  
0.603 NS 
Cases 60.8 ± 11.62 
 
Height (cm) 
Controls 161.53 ± 11.07 
 
0.602 NS
 
Cases 162.93 ± 9.56 
 
BMI (kg/m2) 
Controls 23.89 ± 2.85  
0.282 NS
 
Cases 23.05 ± 3.19 
 
          NS
 -
 Not significant 
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TABLE: 3 
COMPARISON OF PULSE AND B.P. OF BRONCHIAL ASTHMA 
PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
Pulse (bpm) 
Controls 76.33 ± 7.26  
0.523 NS 
Cases 75.27 ± 5.47 
 
Systolic B.P (mmHg) 
Controls 120 ± 8.7  
< 0.01 * 
Cases 112.33 ± 9.35 
 
Diastolic B.P (mmHg) 
Controls 75 ± 9 
 
0.354 NS
 
Cases 73 ± 7.49 
 
 
NS
-
   Not significant  
* - Significant 
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TABLE: 4 
COMPARISON OF FVC, FEV1 AND FEV1%OF BRONCHIAL 
ASTHMA PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
FVC (L) 
Controls 3.65 ± 0.82  
< 0.001 *** 
Cases 2.29 ± 0.70 
 
FEV1 (L) 
Controls 3.11 ± 0.69  
< 0.001 *** 
 Cases 1.56 ± 0.59 
 
FEV1 % 
Controls 84.82 ± 1.92 
 
< 0.001 ***
 
Cases 63.74 ± 7.9 
 
*** - Very highly significant 
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TABLE: 5 
COMPARISON OF FEV25-75% AND PEFR OF BRONCHIAL ASTHMA 
PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
 
FEV25-75% (L) 
 
Controls  
 
3.43 ± 0.42 
 
 
< 0.001 *** 
 
Cases 
 
1.08 ± 0.5 
 
 
PEFR (L/sec) 
 
Controls 
 
7.69 ± 1.25 
 
 
< 0.001 *** 
 
 Cases 
 
3.75 ± 1.79 
 
 
*** - Very highly significant 
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TABLE: 6 
COMPARISON OF MEAN RR AND MEAN HR OF BRONCHIAL 
ASTHMA PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
 
MEAN RR 
 
Controls 
 
0.74 ± 0.1 
 
 
< 0.05 * 
 
Cases 
 
0.81 ± 0.13 
 
 
 
MEAN HR 
 
Controls 
 
83.23 ± 8.7 
 
 
< 0.001 *** 
  
Cases 
 
74.73 ± 6.97  
 
* - Significant 
*** - Very highly significant 
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TABLE: 7 
COMPARISON OF SDNN, RMSSD, NN50 COUNTS AND pNN50% OF 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
SDNN (ms) 
Controls 63.37 ± 27.75  
< 0.001 *** Cases 37.30 ± 18.59 
 
RMSSD 
Controls 51.98 ± 15.59  
< 0.001 *** 
Cases 25.82 ± 9.33 
 
NN50 COUNTS 
Controls 72.57 ± 9.96 
 
< 0.01 **
 
Cases 37.77 ± 6.05 
 
pNN50% 
Controls 27.06 ± 3.16 
 
< 0.001 ***
 
Cases 12.90 ± 2.36 
** - Highly significant   
*** - Very highly significant 
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TABLE: 8 
COMPARISON OF VLF, LF AND HF OF BRONCHIAL ASTHMA 
PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
VLF (ms2) 
Controls 2334.23 ± 520.20  
< 0.01 ** Cases 1289.36 ± 285.89 
 
LF (ms2) 
 Controls 331.07 ± 64.27  
< 0.001 *** 
 Cases 199.4 ± 35.27 
 
HF (ms2) 
Controls  85.9 ± 11.18  
< 0.001 ***
 Cases 143.23 ± 25.46 
 
** - Highly significant 
*** - Very highly significant 
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TABLE: 9 
COMPARISON OF LF n.u, HF n.u AND LF/HF RATIO OF 
BRONCHIAL ASTHMA PATIENTS AND NORMAL SUBJECTS 
 
Parameters Group Mean ± SD p  value 
 
LF n.u 
Controls 69.19 ± 9.72  
0.236 NS Cases 68.89 ± 11.82 
 
HF n.u  
Controls 30.78 ± 9.72  
0.107 NS 
 Cases 33.47 ± 15.79 
 
LF/HF ratio 
Controls 3.85 ± 0.37  
0.108 NS
 Cases 1.66 ± 0.24 
 
NS
 - Not significant 
 
 
 
  
COMPARISON OF 
p value for age is 0.706NS
p value for height is 0.603
p value for weight is 0.602
p value for BMI is 0.282
NS
 – Not significant. 
AGE (years)
31.27 32.03
78 
CHART: 1 
BASELINE CHARACTERISTICS
 
 NS
 
NS
 
 NS 
HEIGHT (cm) WEIGHT (kg) BMI (kg/m2)
161.53
62.4
23.89
162.93
60.8
CONTROLS ASTHMATICS
 
 
23.05
  
COMPARISON OF BLOOD PRESSURE AND PULSE
p value for SBP is < 0.01
p value for DBP is 0.354
p value for pulse rate is 0.523
** - Highly significant   
NS
 – Not significant 
SYSTOLIC B.P
120
112
79 
CHART: 2 
** 
 NS
 
NS
 
DIASTOLIC B.P PULSE RATE
75 76.3373
CONTROLS ASTHMATICS
 
 
75.27
  
COMPARISON OF FVC, FEV
p value for FVC is < 0.001***
p value for FEV1 is < 0.001***
p value for FEV25-75% is < 0.001***
*** - Very highly significant
 
FVC
3.65
2.29
80 
CHART: 3 
1 AND FEV25-75%
 
 
 
   
FEV1 FEV 25-75%
3.11
3.43
1.56
CONTROLS ASTHMATICS
 
 
1.08
  
COMPARISON OF FEV
 
 
p value for FEV1 %  is < 0.001***
*** - Very highly significant
 
CONTROLS
84.82
81 
CHART: 4 
1 % 
 
   
ASTHMATICS
63.74
CONTROLS ASTHMATICS
 
  
 
 
p value for PEFR is < 0.001***
*** - Very highly significant
 
 
CONTROLS
7.69
82 
CHART: 5 
COMPARISON OF PEFR
 
 
   
ASTHMATICS
3.75
CONTROLS ASTHMATICS
 
  
COMPARISON OF 
 
p value for Mean RR is < 0.05*
* - significant   
 
CONTROLS
0.74
CONTROLS
83 
CHART: 6 
MEAN RR
 
 
 
ASTHMATICS
0.81
ASTHMATICS
 
  
COMPARISON OF MEAN HR
 
p value for Mean HR is < 0.001***
*** - Very highly significant
 
CONTROLS
83.23
CONTROLS
84 
CHART: 7 
 
 
 
   
ASTHMATICS
74.73
ASTHMATICS
 
  
COMPARISON OF SDNN AND RMSDD
 
p value for SDNN  is < 0.001***
p value for RMSSD  is < 0.001***
*** - Very highly significant
 
SDNN (ms)
63.37
37.3
85 
CHART: 8 
 
 
 
   
RMSSD
51.98
25.82
CONTROLS ASTHMATICS
 
  
COMPARISON OF NN50 COUNTS AND pNN50%
p value for NN50 counts is < 0.01**
p value for pNN50%  is < 0.001***
** - Highly significant 
*** - Very highly significant
NN50 COUNTS
72.57
37.77
86 
CHART: 9 
 
 
 
   
 
pNN50%
27.06
12.9
CONTROLS ASTHMATICS
 
 
  
 
 
p value for VLF  is < 0.01***
*** - Highly significant  
CONTROLS
2334.23
87 
CHART: 10 
COMPARISON OF VLF
 
 
 
 
ASTHMATICS
1289.36
CONTROLS ASTHMATICS
 
  
COMPARISON OF LF AND HF
 
p value for LF is < 0.001***
p value for HF is < 0.001***
*** - Very highly significant
 
 
LF
331.07
199.4
88 
CHART: 11 
 
 
 
   
HF
85.9
143.23
CONTROLS ASTHMATICS
 
  
COMPARISON OF LFnu AND HFnu
 
p value for LFnu is 0.236
p value for HFnu is 0.107
NS
 – Not significant. 
 
 
LF n.u.
69.19 68.89
89 
CHART: 12 
 
NS
 
 NS 
HF n.u.
30.78
33.47
CONTROLS ASTHMATICS
 
  
COMPARISON OF LF/HF RATIO
 
 
p value for LF/HF ratio is 0.108
NS
 – Not significant.
CONTROLS
3.85
90 
CHART: 13 
 
 NS 
ASTHMATICS
1.66
CONTROLS ASTHMATICS
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DISCUSSION 
 
                                Asthma is chronic inflammatory disorder of the airways, 
cells and cellular elements. Airway hyper responsiveness leads to recurrent 
episodes of wheezing, breathlessness, chest tightness and coughing.  
 
                                Asthma constitutes 1% of the global disease burden. 
Annual worldwide mortality is 2,50,000. Mortality does not correlate with 
prevalence. Because modern clinical practice has revolutionized to find out 
and remove the exciting cause, allay the spasm during the paroxysm and to 
treat complications and sequelae.  
 
                               The prevalence of bronchial asthma may vary within India 
because India is a country with dense population, changing climatic 
conditions, low socioeconomic and educational status, industrialization, traffic 
congestion and increasing number of automobiles, low health status and high 
prevalence of infections. 
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                               An obstructive pattern is seen in pulmonary function tests 
during asthma episodes. This includes a decrease in FEV1 and FEV1/FVC ratio 
due to increased resistance. 
                               
                              There is a reduction in forced vital capacity (FVC) because of 
hyperinflation of the lungs and increased residual volume. These patients breathe 
at such high lung volumes near the top of the pressure-volume curve, where lung 
compliance greatly decreases.  
                                   
                               In order to treat any chronic illness, we need to follow 
guidelines that optimize its diagnosis and management. The Global Initiative 
for Asthma (GINA) committee reports are updated annually.  Its guidelines 
and classifications are changing according to the needs.  This could be due to 
the patient’s awareness to visit the clinician or pulmonologists before it 
interrupts their daily activities.  
                                           
                              Recent advances in pharmacotherapy also prevent the 
progression of disease to the next level. Most patients with positive family 
history present with mild symptoms progress to severe forms early in their life 
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within in a short period of time than others, due to genetic susceptibility. This 
study supports the findings of other similar studies.  
 
                            Autonomic innervations are a primary control mechanism 
regulating HRV and cardiac performance. In normal persons the heart rate has 
a high degree of beat to beat variability and HRV changes with respiration, 
increases during inspiration and decreases during expiration60.  
 
                           HRV denotes the individual’s autonomic tone and frequency 
domain measures are considered as best quantitative method for sympathetic 
and parasympathetic activity. A predominance of parasympathetic activity 
causes bradycardia and increase beat-to-beat variation, whereas increased 
sympathetic tone induces tachycardia and reduce beat-to-beat variations in 
HRV. 
 
                            High beat-to-beat variation is desirable and lower beat-to-
beat variation is an established predictor of cardiac mortality and morbidity. 
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Abnormal HRV predicts the cardiovascular etiology for mortality, coronary 
atherosclerotic development and cardiac arrhythmias.  
                            The mean age, weight and height of the cases and the 
controls had showed no statistical significance. This suggests that the selection 
criterion of the control group was perfect. 
 
                            The pulse of an individual is determined by the balance 
between sympathetic and parasympathetic activity. Decrease in pulse rate 
indicates more of parasympathetic activity and increase in pulse rate indicates 
more of sympathetic activity. In our study the pulse rate of the cases was 
decreased when compared to controls but was not statistically significant.  
                                 
                           The systolic blood pressure depends on cardiac output which 
is the product of stroke volume and heart rate. Increase in sympathetic tone 
increases cardiac output and decrease in sympathetic tone decrease in cardiac 
output. In our study the systolic blood pressure of the cases was decreased 
when compared to that of the controls which was statistically significant. This 
fall in systolic blood pressure in cases could be attributed to decrease in 
sympathetic tone in cases. 
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                                  The diastolic blood pressure depends on peripheral 
resistance. The tone of the blood vessels depends on the impulse transmission 
via peripheral sympathetic nerves to the blood vessels. The diastolic blood 
pressure in the cases was decreased when compared to control which was not 
statistically significant. This decrease in diastolic blood pressure could be 
attributed to decreased impulse transmission from vasomotor centre to blood 
vessels via peripheral sympathetic nerves. 
 
                                Forced vital capacity is the maximum volume of air that is 
breathed out forcefully, rapidly and maximally. There was significant decrease 
in FVC of the cases compared to that of the controls. This is attributed to 
increased cholinergic stimulation which causes bronchoconstriction and air 
trapping causing increased residual volume. 
 
                               FEV1, FEV1%, FEV25-75% and PEFR were decreased in the 
cases compared to the controls due to bronchoconstriction as a result of 
increased cholinergic stimulation. Decreased FEV25-75 % suggest presence of 
small airway obstruction. 
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                                The mean R-R interval of the cases was significantly 
higher than that of the controls while the mean heart rate of the cases was 
significantly lower than that of the controls. This shows that there is increase 
in the parasympathetic tone compared to sympathetic tone. This was different 
from the study done previously by Garrard CS59. They observed increased 
sympathetic tone in asthmatics of longer duration. 
 
                                 SDNN, RMSSD, NN50 counts and pNN50% estimate 
high frequency variations in the heart rate. These parameters in the cases were 
significantly less compared to that of the controls. This suggests that high 
frequency variations in the heart rate were decreased in cases compared to the 
controls. High beat to beat variation is desirable and low beat to beat variation 
is a predictor of cardiac mortality and morbidity. 
                                 
                                    LF and LF nu denote sympathetically mediated HRV. 
LF was significantly reduced but the decrease of LF nu in cases was not 
statistically significant. This suggests that low frequency variation in the heart 
rate is less and sympathetic tone is decreased. This finding was similar to the 
studies done previously by Du J51 and Gupta J54. 
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                                  HF and HF nu denote parasympathetically mediated 
HRV. HF was significantly increased in the cases while the increase of HF nu 
in cases was not statistically significant. This suggests that high frequency 
variation in the heart rate were more and parasympathetic tone was increased. 
This was similar to the studies done previously by Lutfi MF47 and Gupta J54. 
 
                                  LF/HF ratio of the cases was decreased than that of the 
controls but was not statistically significant. The LF/HF ratio measures 
sympathovagal balance and the primary cause for decreased LF/HF ratio in 
asthmatics was parasympathetic dominance than sympathetic dysfunction. 
This was similar to the study done by Gupta J54. 
 
                                 90% (27 out of 30) of bronchial asthma patients had 
positive family history. Chi square test for correlation of family history with 
bronchial asthma showed an odds ratio of 45. This shows that bronchial 
asthma patients with positive family history have 45 times more chance of 
getting asthma than those with negative family history. 
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                                FEV1% showed significant negative correlation with HF of 
frequency domain measures i.e., as FEV1% decreases parasympathetic activity 
increases. This suggests that parasympathetic tone increases with the severity 
of the asthma.   
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CONCLUSION 
 
• Spectral analysis of short term heart rate variability is a useful tool for 
quantifying ANS activities. 
 
• In this study, we found out the autonomic dysfunctions in bronchial asthma 
by using spectral analysis of heart rate variability.  
 
• Bronchial asthma initially affects parasympathetic nervous system and has 
a mild impact on sympathetic nervous system. 
 
• Time domain measures of HRV showed significant parasympathetic 
dominance in asthmatics. The frequency domain measures also showed 
increased parasympathetic activity.   
 
 
• Correlation of high frequency with FEV1% by Pearson correlation 
statistical analysis showed negative correlation which means there was an 
increase in parasympathetic activity with increase in severity of asthma.  
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• To conclude, a significantly raised central vagal outflow and a concomitant 
low central sympathetic outflow is observed in asthmatics.  
 
• This deranged sympathovagal balance with parasympathetic dominance 
could be the probable cause leading to airway obstruction in bronchial 
asthma.   
 
• Low beat to beat variability was observed in asthmatics which is a predictor 
of cardiac mortality and morbidity. 
 
• Most patients with bronchial asthma had positive family history. Since 
genetic susceptibility is a non modifiable factor, the environmental factors 
can be avoided. 
 
• Identifying positive family history of asthma provides a basis for the 
preventive efforts to target the environmental risk factors.  
 
• Unless prevented, asthmatic attacks can hinder day to day activities and 
cause significant reduction in quality of life.  
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ANNEXURE
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A STUDY OF AUTONOMIC MODULATIONS WITH SHORT TERM 
HEART RATE VARIABILITY IN BRONCHIAL ASTHMA PATIENTS 
AND ITS CORRELATION WITH PULMONARY FUNCTION TESTS 
 PROFORMA  
Name: 
Age: 
Sex: 
IP /OP Number: 
Occupation: 
Address: 
HISTORY REGARDING THE CASE 
Duration of Illness 
PAST HISTORY      
Hypertension 
Diabetes           
 Any Other illness 
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PERSONAL HISTORY 
      Food Habits:  
       Exercise       : 
       Smoking      : 
       Alcohol       : 
       Tobacco Chewing: 
FAMILY HISTORY   
      Any Similar Problems: 
 DRUG HISTORY 
    Details of asthma treatment: 
    Details of any other drug intake: 
EXAMINATION OF THE PATIENT: 
 GENERAL EXAMINATION 
 Nutrition 
 Build 
Clubbing 
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Cyanosis  
Jaundice 
Anemia 
Pulse rate 
Resting BP 
SYSTEMIC EXAMINATION: 
 Examination of CVS 
 Examination of RS 
 Examination of ABDOMEN 
 Examination of CNS 
INVESTIGATIONS: 
 Pulmonary Function Test  
ANTHROPOMETRIC MEASUREMENTS 
HEIGHT in cms 
WEIGHT in kgs 
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HEART RATE VARIABILITY 
FREQUENCY DOMAIN MEASURES: 
    LF POWER 
    HF POWER 
    LF/HF RATIO 
     LF nu 
     HF nu 
TIME DOMAIN MEASURES  
 Mean RR 
Mean HR 
 SDNN 
 RMSSD 
 NN50 
 PNN50       
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CONSENT FORM 
              A study of autonomic modulations with short term heart rate 
variability in bronchial asthma patients and its correlation with 
pulmonary function tests 
MD Thesis research project 
Department Of physiology 
PSG IMS &R. 
 
I,……………….. have been explained about the purpose of the research study 
on HRV analysis. I have received verbal information on the above study and 
on the possible benefits and discomforts of ECG recording. I have been given 
chance to discuss the study and ask questions. 
      By signing this form, I give my consent to take part in this study and I am 
aware that my participation is entirely voluntary. I agree that my personal data 
including data relating to my physical or mental health may be used for this 
study. I have been assured that the information from this study, if published in 
scientific journals or presented at scientific meetings, will not reveal my 
identity. 
                                             Truly, 
                                               ………………………  
                                            (Subject name, signature) 
                                             WITNESS: 
                                             DATE AND TIME: 
 
  
 
ASTHMATICS DATA SHEET 
S.NO AGE 
years 
HEIGHT 
cm 
WEIGHT 
kg 
BMI 
Kg/m2 
FVC 
L 
FEV1 
L 
FEV1% 
% 
FEV25-75% 
L/sec 
PEFR 
L/sec 
PULSE 
bpm 
SBP 
mmHg 
DBP 
mmHg 
1 28 165 63 23.1 1.6 0.89 55.6 0.46 1.58 72 110 70 
2 20 150 46 20.4 2.56 1.8 70.3 1.3 3.8 74 120 70 
3 43 167 71 25.5 2.63 1.81 69.5 1.27 4.16 78 100 60 
4 45 175 80 26.1 2.29 1.53 64.7 0.85 3.93 78 100 70 
5 38 169 74 25.9 2.43 1.62 65.7 1.01 4.37 80 120 80 
6 35 151 51 22.4 1.84 1.4 76 1.15 3.31 76 110 70 
7 41 157 53 21.5 1.91 1.48 65 1.3 2.81 68 130 80 
8 24 166 73 26.5 2.9 2.17 73.5 1.62 6.5 88 120 80 
9 20 150 41 18.2 1.26 0.78 59.4 0.68 1.74 84 120 80 
10 20 176 66 21.3 3.3 2.19 66.1 1.26 5.59 76 110 70 
11 33 163 57 21.5 2.24 1.16 51.9 0.54 3.15 68 110 70 
12 43 171 51 17.4 2.03 0.87 43.3 0.47 1.66 66 120 80 
13 37 156 60 24.7 1.63 0.91 56 0.47 1.46 70 110 60 
14 45 167 89 31.9 2.53 1.89 64.4 1.45 5.35 72 100 60 
15 22 155 50 20.8 2.25 1.77 67.9 1.57 3.92 74 110 80 
  
 
S.NO AGE 
years 
HEIGHT 
cms 
WEIGHT 
kg 
BMI 
Kg/m2 
FVC 
L 
FEV1 
L 
FEV1% 
% 
FEV25-75% 
L/sec 
PEFR 
L/sec 
PULSE 
bpm 
SBP 
mmHg 
DBP 
mmHg 
16 28 156 56 23 1.5 1.14 67 0.99 1.76 78 120 80 
17 45 153 63 26.9 1.6 1.24 64.3 0.95 3.6 82 110 70 
18 38 175 71 23.2 2.89 1.78 61.1 0.89 5.3 80 100 70 
19 31 165 62 22.8 2.9 2.35 66.6 1.71 5.62 84 100 60 
20 29 176 67 21.6 4.13 2.83 68.4 1.86 6.32 68 110 70 
21 24 162 54 20.6 2.6 1.78 71.5 1.3 4.28 68 110 70 
22 20 174 47 18.5 2.16 1.08 49.3 0.56 2.34 72 110 80 
23 37 149 49 22.1 1.34 0.86 69.3 0.58 2.41 70 100 70 
24 29 150 57 25.3 1.2 0.67 55.8 0.32 1.33 74 120 80 
25 39 155 63 26.2 2.1 1.24 58.6 0.65 2.92 74 120 70 
26 31 160 62 24.2 2.15 1.13 52.5 0.56 1.79 72 110 70 
27 40 157 67 27.2 2.33 1.78 65.2 1.47 3.96 78 110 70 
28 27 183 78 23.3 3.75 2.86 73.7 2.01 8.65 76 130 80 
29 29 162 41 18.6 1.79 1.33 72.7 0.96 3.22 78 130 90 
30 20 173 62 20.7 2.96 2.33 67 2.08 5.88 80 100 80 
  
 
 
S.NO FAMILY 
H/O 
Mean 
RR 
Mean 
HR 
SDNN 
ms 
RMSSD 
ms 
NN50 
counts 
pNN50 
% 
VLF 
ms2 
LF 
ms2 
HF 
ms2 
LF/HF LF 
nu 
HF 
nu 
1 YES 0.627 96 29.308 14.565 6 1.3 60 198 481 1.75 66.3 33.7 
2 YES 0.64 94 38.527 26.975 28 6.5 260 195 375 3.4 79.4 20.6 
3 YES 0.756 79 32.37 38.887 24 25.3 493 178 84 1.83 66.7 33.3 
4 NO 0.752 80 93.4 39.971 58 47.5 1757 236 115 1.6 64 36 
5 YES 0.69 87 30.76 19.301 7 1.7 326 131 4 3.75 84.4 15.2 
6 YES 0.854 70 24.608 24.202 6 1.7 992 98 178 1.52 65.2 35.3 
7 YES 0.705 85 16.787 13.041 10 2.1 1879 263 22 1.72 64.5 35.3 
8 YES 0.697 86 47.23 39.034 24 25 2536 52 79 2.93 77 23 
9 YES 0.77 78 39.696 26.629 20 4.7 360 120 95 4.65 84.8 15.2 
10 YES 0.813 74 87.922 29.509 87 35.1 6687 1006 238 1.15 54.7 45.3 
11 NO 0.717 84 38.419 34.35 71 14.2 45 158 39 3.43 78.3 21.7 
12 YES 0.792 76 24.3 20.815 2 0.5 1045 182 112 2.35 73 27 
13 YES 0.864 82 38.701 20.075 75 21.6 2985 171 48 3.02 76.6 24 
14 YES 0.711 84 30.62 30.42 37 8.9 367 178 29 1.86 66.4 33.6 
15 YES 0.831 72 65.502 36.871 126 40.8 663 227 112 3.54 81.6 90.2 
  
 
S.NO FAMILY 
H/O 
Mean 
RR 
Mean 
HR 
SDNN 
ms 
RMSSD 
ms 
NN50 
counts 
pNN50 
% 
VLF 
ms2 
LF 
ms2 
HF 
ms2 
LF/HF LF 
nu 
HF 
nu 
16 NO 0.846 71 44.179 35.171 48 13.5 3503 403 87 0.63 50 50 
17 YES 0.888 88 51.06 22.083 102 30.5 2186 215 59 1.16 55.9 44.1 
18 YES 0.849 71 42.219 34.446 49 13.9 2483 192 26 2.84 77.5 22.7 
19 YES 0.831 72 34.742 33.454 50 13.6 920 143 37 1.81 38.1 61.9 
20 YES 0.696 86 23.15 21.672 13 2.9 91 71 95 3.15 78.4 21.6 
21 YES 0.618 97 33.756 15.283 1 0.2 60 36 413 2.43 74.7 25.3 
22 YES 0.564 96 18.833 12.858 20 4.3 29 33 7 1.71 80.5 19.3 
23 NO 0.778 77 29.209 27.511 29 7.3 900 156 317 2.91 76.9 23.1 
24 YES 0.57 95 11.342 21.551 40 11.9 15 38 252 2.35 72.7 27.3 
25 YES 0.773 78 36.687 35.714 77 19.4 841 168 107 2.57 74 26 
26 YES 0.581 93 20.929 9.546 30 6.9 22 29 314 2.5 76.3 22.5 
27 YES 0.802 75 48.148 18.767 2 0.6 2551 356 51 0.74 46.6 53.4 
28 NO 0.7 86 21.917 21.04 14 3.2 254 135 27 1.25 57.3 42.4 
29 YES 0.562 97 21.15 11.913 2 0.4 19 30 422 2.06 69.6 30.4 
30 YES 0.888 88 43.712 38.995 75 21.7 4352 584 72 1.16 55.4 44.6 
  
 
 
 
 
 
 
 
 
  
 
CONTROLS DATA SHEET 
S.NO AGE 
years 
HEIGHT 
cm 
WEIGHT 
kg 
BMI 
Kg/m2 
FVC 
L 
FEV1 
L 
FEV1% 
% 
FEV25-75% 
L/sec 
PEFR 
L/sec 
PULSE 
bpm 
SBP 
mmHg 
DBP 
mmHg 
1. 20 160 55 21.5 3.93 3.47 84.3 3.01 7.83 74 120 80 
2. 20 154 50 21.08 3.9 3.46 84.83 3.6 7.48 72 120 70 
3. 37 152 61 26.4 3.41 3.08 86.31 3.6 5.86 70 130 80 
4. 42 160 72 28.1 3.9 3.48 85.52 3.86 7.26 78 110 70 
5. 29 175 66 21.6 4.8 4.04 86.24 3.82 9.81 76 130 80 
6. 31 170 69 23.88 4.48 3.85 85.94 4.19 8.04 80 130 80 
7. 43 180 81 25 4.15 3.61 82.86 3.51 8.2 84 130 90 
8. 31 167 57 20.5 4.57 3.67 80.31 3.35 8.69 62 110 60 
9. 25 172 83 28.1 4.94 4.21 85.22 3.9 8.12 76 120 70 
10. 28 157 54 25.96 3.34 2.8 83.78 3.31 7.43 74 110 70 
11. 32 152 58 25.2 2.56 2.24 87.5 2.88 7.2 82 120 70 
12. 33 160 65 25.4 4.02 3.43 85.32 3.38 7.56 76 120 80 
13. 26 182 70 21.2 4.17 3.42 83.01 3.51 9.68 76 120 80 
14. 32 175 88 28.7 4.85 3.99 82.27 3.79 9 80 130 80 
15. 25 160 50 19.5 3.24 2.81 86.73 3.19 6.34 66 120 70 
  
 
S.NO AGE 
years 
HEIGHT 
cm 
WEIGHT 
kg 
BMI 
Kg/m2 
FVC 
L 
FEV1 
L 
FEV1% 
% 
FEV25-75% 
L/sec 
PEFR 
L/sec 
PULSE 
bpm 
SBP 
mmHg 
DBP 
mmHg 
16. 24 147 46 21.3 3.02 2.61 87.04 2.89 6.1 84 130 90 
17. 36 144 45 21.7 2.74 2.31 84.31 2.9 7.46 80 130 80 
18. 34 170 80 27.7 3.66 3.11 84.97 3.84 9.18 84 110 60 
19. 42 165 70 25.7 3.62 3.02 82.31 3.62 7.62 90 110 70 
20. 38 154 56 23.6 2.82 2.34 82.98 3.27 6.45 76 120 80 
21. 32 154 67 28.5 2.83 2.4 84.81 3.26 7.46 74 130 90 
22. 21 175 66 21.3 4.53 3.84 84.77 3.87 8.75 84 120 70 
23. 23 170 71 24.5 3.98 3.39 85.18 3.93 8.62 74 130 90 
24. 26 167 52 18.6 3.97 3.26 82.12 3.67 9.29 64 110 60 
25. 30 175 78 25.5 4.99 4.19 83.97 3.85 9.85 84 120 70 
26. 42 149 56 25.22 2.2 1.84 83.64 2.49 5.37 64 110 70 
27. 37 144 46 22.1 2.59 2.29 88.42 2.83 7.43 74 110 70 
28. 40 149 47 21.17 2.5 2.01 88.08 2.74 5.67 84 100 60 
29. 22 150 51 22.66 3.18 2.78 87.42 3.25 6.54 64 120 80 
30. 37 157 62 25.15 2.62 2.22 84.73 3.47 6.5 84 130 80 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
S.NO FAMILY 
H/0 
Mean 
RR 
Mean 
HR 
SDNN 
ms 
RMSSD 
ms 
NN50 
counts 
pNN50 
% 
VLF 
ms2 
LF 
ms2 
HF 
ms2 
LF/HF LF 
nu 
HF 
nu 
1. NO 0.791 76 68.896 49.232 99 32.2 6204 846 32 6.33 86.4 13.6 
2. NO 0.815 74 62.814 58.766 128 49.2 7073 1275 129 1.46 59.3 40.5 
3. NO 1.095 65 90.464 85.744 39 50.6 3359 154 82 2.51 71.6 28.4 
4. NO 1.053 67 151.348 78.352 54 50.5 4279 185 106 2.52 71.6 28.4 
5. NO 0.737 81 78.971 46.336 70 48.6 65 15 55 2.48 71.5 28.8 
6. NO 0.759 79 54.872 36.867 72 19.1 784 272 76 1.37 57.9 42.1 
7. NO 0.654 76 79.417 46.034 62 12.4 18 38 82 8.4 80.8 19.2 
8. NO 0.939 64 57.309 34.036 51 14.2 2434 232 23 2 66.7 33.3 
9. NO 0.766 78 42.549 37.61 28 7.4 1548 442 65 2.47 71.2 28.8 
10. NO 0.793 76 57.569 56.651 138 44.8 1328 274 272 4.46 81.7 18.3 
11. YES 0.716 84 31.918 77.724 24 9.9 87 134 37 1.24 80.2 19.8 
12. NO 0.8 75 38.069 30.7 36 9.4 1727 264 65 3.64 79.1 21.7 
13. NO 0.776 77 33.205 72.446 27 11.8 737 145 145 4.5 60 40 
14. NO 0.758 70 105.8 48.488 33 10.6 43 54 83 5.27 65.5 34.5 
15. NO 0.961 62 62.924 35.144 49 14.9 1603 397 186 1.34 57.3 42.7 
  
 
S.NO FAMILY 
H/0 
Mean 
RR 
Mean 
HR 
SDNN 
ms 
RMSSD 
ms 
NN50 
counts 
pNN50 
% 
VLF 
ms2 
LF 
ms2 
HF 
ms2 
LF/HF LF 
nu 
HF 
nu 
16. NO 0.691 78 33.901 36.099 96 18.7 40 55 165 2.76 72.5 26.5 
17. NO 0.739 81 99.305 33.188 51 11.8 151 69 101 2.61 72.3 27.7 
18. YES 0.686 76 32.977 50.816 28 14.7 145 74 88 2.53 71.7 28.3 
19. NO 0.642 76 96 55.639 33 17.3 49 67 79 2.17 68.5 31.5 
20. NO 0.792 76 30.382 64.071 25 14 2120 300 46 1.64 62.3 37.9 
21. NO 0.801 75 52.589 62.628 155 54.7 7232 1005 22 2.3 70.2 29.8 
22. NO 0.712 84 34.755 43.168 25 21.1 19 12 23 1.81 64.5 35.5 
23. NO 0.85 75 62.221 52.87 89 41.8 6964 925 58 3.09 75.6 24.4 
24. NO 0.936 64 50.294 52.569 148 41.8 4100 593 41 1.00 50.1 50 
25. NO 0.704 85 48.635 30.717 46 11.5 1164 276 69 3.5 77.8 22.2 
26. NO 0.958 63 44.965 59.078 156 49.2 6422 801 23 1.32 56.9 43.1 
27. NO 0.759 75 81.995 35.889 88 18.9 48 38 108 3.88 79.5 20.5 
28. NO 0.718 84 84.212 53.093 45 31.1 112 34 52 2.83 73.9 26.1 
29. NO 1.124 63 47.478 79.301 256 63.7 9958 872 37 10.04 45.5 54.5 
30. NO 0.724 83 85.214 56.162 26 15.9 214 84 227 2.91 73.7 25.3 
